GlassScriptPhysician profile
Lorenzo Munoz
NPI 1124014766
$5,121.89
in general payments reported to CMS, 2019-2025
27 companies · $525 in 2025
The $525 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,219 · 2020: $291 · 2021: $724 · 2022: $863 · 2023: $958 · 2024: $542 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $968.11 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $950.99 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $527.69 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $475.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $386.89 | 2019-2023 | |
| Glaxosmithkline, LLC. | $360.24 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $261.50 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $193.71 | 2019-2021 | |
| Genentech USA, INC. | $125.00 | 2019 | |
| Pfizer INC. | $123.41 | 2021-2025 | |
| Shire North American Group INC | $121.07 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.73 | 2022-2024 | Jardiance |
| Eisai INC. | $87.03 | 2020-2021 | |
| Amarin Pharma, INC. | $78.05 | 2020-2021 | |
| Abbott Laboratories | $61.03 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.52 | 2021-2025 | Repatha, Repatha, Otezla |
| Angiodynamics, INC. | $34.56 | 2025 | Auryon Laser System 100-120 Vac |
| W. L. Gore & Associates, INC. | $30.86 | 2021 | |
| Cipher Pharmaceuticals US LLC | $28.72 | 2025 | Natroba, Spinosad |
| Takeda Pharmaceuticals U.S.A., INC. | $24.87 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.25 | 2024 | Eliquis |
| Sumitomo Pharma America, INC. | $19.64 | 2023 | Gemtesa |
| Insmed, INC. | $15.11 | 2023 | Arikayce |
| Xeris Pharmaceuticals, INC. | $13.26 | 2021 | |
| Phadia US INC. | $12.32 | 2019 | |
| Horizon Therapeutics Plc | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorenzo Munoz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.